Compare LAC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | SNDX |
|---|---|---|
| Founded | 2023 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2023 | 2014 |
| Metric | LAC | SNDX |
|---|---|---|
| Price | $4.54 | $18.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $6.14 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 11.5M | 1.5M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $2.47 | $8.59 |
| 52 Week High | $10.52 | $25.59 |
| Indicator | LAC | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 39.71 |
| Support Level | $4.40 | $14.53 |
| Resistance Level | $5.40 | $22.40 |
| Average True Range (ATR) | 0.33 | 0.79 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 19.04 | 38.78 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.